P
Patrick A. Baeuerle
Researcher at Amgen
Publications - 314
Citations - 59914
Patrick A. Baeuerle is an academic researcher from Amgen. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 115, co-authored 305 publications receiving 57875 citations. Previous affiliations of Patrick A. Baeuerle include University of Freiburg & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Chlorate a potent inhibitor of protein sulfation in intact cells
TL;DR: The effect of chlorate on protein sulfation in intact cells was investigated and chlorate treatment provides a powerful tool for studying the biological significance ofprotein sulfation.
Journal ArticleDOI
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB.
Heike L. Pahl,B. Krauss,Klaus Schulze-Osthoff,Thomas Decker,E. B.-M. Traenckner,M. Vogt,C. Myers,T. Parks,P. Warring,A. Muhlbacher,A.-P. Czernilofsky,Patrick A. Baeuerle +11 more
TL;DR: It is reported that nanomolar concentrations of gliotoxin inhibited the activation of transcription factor NF-kappaB in response to a variety of stimuli in T and B cells, raising the possibility that the immunosuppression observed during aspergillosis results in part from gliot toxin-mediated NF- kappaB inhibition.
Journal ArticleDOI
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler,Stefan Knop,Andreas Viardot,Peter Kufer,Max S. Topp,Hermann Einsele,Richard Noppeney,Georg Hess,Stefan Kallert,Andreas Mackensen,Kathrin Rupertus,Lothar Kanz,Martin Libicher,Dirk Nagorsen,Gerhard Zugmaier,Matthias Klinger,Andreas Wolf,Brigitte Dorsch,Beate D. Quednau,Margit Schmidt,Scheele Juergen,Patrick A. Baeuerle,Eugen Leo,Ralf C. Bargou +23 more
TL;DR: In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m(2)/day that showed antilymphoma activity.
Journal ArticleDOI
DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition.
TL;DR: A comparative analysis of known NF-kappa B-binding sites and competition experiments with synthetic polynucleotides and oligonucleotide encompassing only one half-site or single-stranded kappa B motifs suggested that the two DNA-binding monomers in the NF-Kappa B protein complex can interact differentially with the half-sites of the decameric cognate motif.
Journal ArticleDOI
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
Torsten Dreier,Grit Lorenczewski,Christian Brandl,Patrick Hoffmann,Uwe Syring,Frank Hanakam,Peter Kufer,Gert Riethmüller,Ralf C. Bargou,Patrick A. Baeuerle +9 more
TL;DR: In this article, the authors explored the in vitro efficacy, T-cell donor variability, binding characteristics, specificity, kinetics and interleukin-2 (IL-2) dependence of bispecific antibody (bscCD19xCD3) against human B lymphoma cell lines.